melanocortin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Dissolves readily in aqueous buffer |
| Typical storage temperature | -20 °C or below | Protect from light and moisture |
| Typical analytical method | Reversed-phase HPLC and LC-MS | Purity estimate plus mass confirmation |
| Unit of measure | Milligram per vial | Content varies by vendor |
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
== Semiconductor == The total current flow in the semiconductor consists of drift current and diffusion current of both the electrons in the conduction band and holes in the valence band. General form for electrons in one-dimension:
In 2018, Stein opened a second Rick Stein at Bannisters in Salamander Bay in Port Stephens, with his second wife, Sarah. Stein has become a popular television presenter on food programmes. After appearing once as a guest chef in Keith Floyd's 1985 series Floyd on Fish and in his 1986 series Floyd on Food, he was offered the chance to present his own series – like the "travelogue" style of cookery show pioneered by Floyd – on BBC television, using Floyd's producer and director David Pritchard. His shows have included Rick Stein's Taste of the Sea, Fruits of the Sea, Seafood Odyssey, Fresh Food, Seafood Lovers' Guide, Food Heroes, French Odyssey, Mediterranean Escapes, Far Eastern Odyssey, Rick Stein's Spain and Rick Stein's India. In the last five series, he set out in search of the best in the region's foods. Stein was often accompanied by his Jack Russell Terrier, Chalky, until his death in 2007. So popular was Chalky that Sharp's Brewery named two speciality beers after him. A book has accompanied each series, and Stein's book English Seafood Cookery won the Glenfiddich Award for Food Book of the Year in 1989. Stein was awarded the OBE in the 2003 New Year Honours for services to tourism in Cornwall and the CBE in the 2018 New Year Honours for services to the economy. On 22 June 2020, it was confirmed that Stein's restaurant in Porthleven, Cornwall, would close permanently due to the COVID-19 pandemic. The restaurant had been closed since March 2020. In July 2020, it was announced that chef Michael Caines would take over the restaurant.
The Banting Postdoctoral Fellowship Program is administered by the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, and the Social Sciences and Humanities Research Council of Canada. The fellowship provided up to two years of funding at $70,000 per year to researchers in health, natural sciences, engineering, social sciences and humanities.
=== 2016–present: Move to Melbourne and suspension === Citing his friendship with incoming coach, Simon Goodwin, as the key reason for his move to Melbourne, Melksham noted the opportunity for a fresh start as another reason for his move. Melksham, along with 33 other Essendon players, were found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, however, a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 season. After missing twelve months of football, Melbourne elected to ease Melksham back into training heading into the 2017 season, in which he did not join full training until January. With the intention to play the season on the half-back line and the wing, he played his first competitive match in Melbourne colours in the opening week JLT Community Series match against the Western Bulldogs at Whitten Oval playing as a defender. After playing all three matches in the JLT Community Series, he made his debut for Melbourne in the thirty point win against St Kilda at Etihad Stadium in round one.
Sources: en.wikipedia.org
Recent studies have detected the presence of significant levels of dioxins in the commercial shrimp Aristeus antennatus and significant levels of persistent organic pollutants in mesopelagic and bathypelagic cephalopods. Climate-driven processes and climate change will affect the frequency and intensity of cascading, with unknown effects on the benthic fauna. Another potential effect of climate change is related to energy transport from surface waters to the seafloor. Primary production will change in the surface layers according to sun exposure, water temperature, major stratification of water masses, and other effects, and this will affect the food chain down to the deep seafloor, which will be subject to differences in quantity, quality, and timing of organic matter input. As commercial fisheries move into deeper waters, all of these effects will affect the communities and populations of organisms in cold seeps and the deep sea in general.
== Board of directors == The board of directors is composed of thirteen members, in office until the approval of the financial statements at 31 December 2020, with Alberto Vacchi in the role of chairman and executive CEO. Marco Vacchi is the honorary president.
Besides inhibiting human acetylcholinesterase (although to a lesser degree than the insect enzyme), carbamate insecticides also target human melatonin receptors. The human health effects of carbamates are well documented in the list of known endocrine disruptor compounds. Clinical effects of carbamate exposure can vary from slightly toxic to highly toxic depending on a variety of factors including such as dose and route of exposure with ingestion and inhalation resulting in the most rapid clinical effects. These clinical manifestations of carbamate intoxication are muscarinic signs, nicotinic signs, and in rare cases central nervous system signs.
Sources: en.wikipedia.org
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.
Reversed-phase liquid chromatography estimates purity, and mass spectrometry confirms molecular mass. Together they distinguish the intended peptide from truncated or modified forms. Sequence-level confirmation may use tandem mass spectrometry or amino acid analysis.
Because it is not made under pharmaceutical standards, purity and content can vary between vendors and batches. Independent testing has documented labeling discrepancies. A certificate of analysis from an accredited laboratory offers more assurance than a vendor's own claim.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.